Skip to main content

Reversible posterior encephalopathy syndrome associated with bortezomib

Buy Article:

$43.00 plus tax (Refund Policy)

Reversible posterior encephalopathy (RPES) is an uncommon neurological syndrome that is being increasingly reported in association with anti‐neoplastic therapies. The first case of reversible posterior encephalopathy associated with the proteosome inhibitor bortezomib is described and the reported experience of the occurrence of RPES with other antineoplastic therapies reviewed. Dysregulation of cerebral vasomotor autoregulation is postulated as the underlying pathophysiology in this case of bortezomib associated RPES.
No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Keywords: bortezomib; proteosome inhibitor; reversible posterior encephalopathy

Document Type: Research Article

Affiliations: Departments of Haematology and

Publication date: 2010-01-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more